title: Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams.
abstract: OBJECTIVE
  To determine whether exposure to antenatal corticosteroid therapy was associated with adverse effects on growth, sensorineural outcome, or lung function of children of birth weight <1501 g at 14 years of age.
  
  
  METHODS
  Cohort study.
  
  
  METHODS
  The Royal Women's Hospital, Melbourne, Australia.
  
  
  METHODS
  One hundred fifty-four consecutive survivors born from October 1, 1980 to March 31, 1982.
  
  
  METHODS
  The mothers of 78 survivors (51%) had been given corticosteroids antenatally to accelerate fetal lung maturation. Treatment with antenatal corticosteroids was nonrandom. No mother received >1 course of corticosteroids.
  
  
  METHODS
  The children were assessed at 14 years of age, corrected for prematurity. All assessors were unaware of the exposure of the child to antenatal corticosteroids. The assessments included measurements of growth and neurological, cognitive, and lung function. Growth measurements were converted into z scores (standard deviation) for the appropriate age and gender.
  
  
  RESULTS
  Of the 154 survivors, 130 (84%) were assessed at 14 years of age. Overall, the children exposed to antenatal corticosteroids were significantly taller (height z score; mean difference:.39; 95% confidence interval:.001-. 79) and had better cognitive functioning (Wechsler Intelligence Scale for Children-Third Edition Full Scale; IQ mean difference: 6. 2; 95% confidence interval:.8-11.6) than those not exposed to corticosteroids. There were no other differences in sensorineural outcomes between the groups. Lung function was not significantly different between the groups. No conclusions were altered by adjustment for confounding variables.
  
  
  CONCLUSIONS
  Exposure to 1 course of antenatal corticosteroid therapy was associated with some clinically and statistically improved outcomes at 14 years of age in children of birth weight <1501 g, with no obvious adverse effects on growth or on sensorineural, cognitive, or lung function. corticosteroids, growth, cognitive, IQ, lung function, adolescence.
authors.affiliation: Division of Newborn Services, Royal Women's Hospital, Melbourne, Australia. l.doyle@obgyn-rwh.unimelb.edu.au
authors.forename: L W
authors.initials: LW
authors.lastname: Doyle
authors.forename: G W
authors.initials: GW
authors.lastname: Ford
authors.forename: A L
authors.initials: AL
authors.lastname: Rickards
authors.forename: E A
authors.initials: EA
authors.lastname: Kelly
authors.forename: N M
authors.initials: NM
authors.lastname: Davis
authors.forename: C
authors.initials: C
authors.lastname: Callanan
authors.forename: A
authors.initials: A
authors.lastname: Olinsky
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D003071:Cognition / Q000502:physiology; D015331:Cohort Studies; D005260:Female; D005325:Fetal Organ Maturity / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007230:Infant, Low Birth Weight / Q000502:physiology*; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology; D008297:Male; D011247:Pregnancy
chemical_list: D000305:Adrenal Cortex Hormones